**SUPPLEMENTARY TABLE AND FIGURES**

David J. Portman, Steven R. Goldstein, Risa Kagan.

Treatment of moderate to severe dyspareunia with intravaginal prasterone therapy: a review. *Climacteric* 2018.

**Supplementary Table 1.** Prasterone table of studies.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| *Phase* | *NCT ID (publication)* | *Number enrolled* | *Duration* | *Treatment* | *Primary outcomes* |
| 1/2 | NCT00429806 (Labrie *et al.* 2008[[1](#_ENREF_1)]) | 40 | 1 week | Prasterone (0.5%, 1.0%, and 1.8%)  Placebo | Systemic bioavailability of DHEA and its metabolites  Pharmacokinetics at 4 different DHEA concentrations |
| 3 | NCT01846442 (Labrie *et al.* 2009[[2](#_ENREF_2)]) | 218 | 12 weeks | Prasterone (0.25%, 0.5%, 1.0%)  Placebo | Change from baseline to week 12a:  Vaginal cell maturation (percentage of parabasal cells and superficial cells)  Vaginal pH  Self-assessed severity of the MBS dyspareunia |
| 3b | NCT01256671 (Labrie *et al.* 2015; Bouchard *et al.* 2016[[3](#_ENREF_3), [4](#_ENREF_4)]) | 530 | 52 weeks | Prasterone (0.5%) | Long-term (52 weeks or discontinuation) safety: endometrium  Serum steroid levels |
| 3b | NCT01256684 (Archer *et al.* 2015[[5](#_ENREF_5)]) | 255 | 12 weeks | Prasterone (0.25%, 0.50%)  Placebo | Change from baseline to week 12a:  Vaginal cell maturation (percentage of parabasal cells and superficial cells)  Vaginal pH  Self-assessed severity of the MBS dyspareunia |
| 3 | NCT01358760 (Bouchard *et al.* 2015[[6](#_ENREF_6)]) | 450 | 12 weeks | Prasterone (0.25%, 0.5%)  Placebo | Change from baseline to week 12a:  Vaginal cell maturation (percentage of parabasal cells and superficial cells)  Vaginal pH  Self-assessed severity of the MBS dyspareunia |
| 3b | NCT02013544 (Labrie *et al.* 2016[[7](#_ENREF_7)]) | 558 | 12 weeks | Prasterone (0.50%)  Placebo | Change from baseline to week 12a:  Vaginal cell maturation (percentage of parabasal cells and superficial cells)  Vaginal pH  Self-assessed severity of the MBS dyspareunia |

DHEA, dehydroepiandrosterone; MBS, most bothersome symptom; NCT ID, National Clinical Trial identifier. aCo-primary endpoints; bpivotal study.

**Supplementary Figure 1.** Postmenopausal sources of sex steroids. A, androgens; ACTH, adrenocorticotropic hormone; CRH, corticotropin releasing hormone; DHEA, dehydroepiandrosterone; E, estrogen; GnRH, gonadotropin releasing hormone; LH, luteinizing hormone.

[Adapted from Labrie F and Labrie C. *Climacteric*. 2013;16(2):205-213]



**Supplementary Figure 2.** Change in moderate to severe dyspareunia score in the 52-week safety study. Score based on severity of dyspareunia: none = 0, mild = 1, moderate = 2, and severe = 3. \**p* < 0.0001 vs. placebo.

[Adapted from Labrie F, et al. *Maturitas.* 2015;81:46-56]



**REFERENCES**

1. Labrie F, Cusan L, Gomez JL, et al. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women. *J Steroid Biochem Mol Biol.* 2008;111:178-94.

2. Labrie F, Archer D, Bouchard C, et al. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. *Menopause.* 2009;16:907-22.

3. Labrie F, Archer DF, Bouchard C, et al. Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study. *Maturitas.* 2015;81:46-56.

4. Bouchard C, Labrie F, Derogatis L, et al. Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study. *Horm Mol Biol Clin Investig.* 2016;25:181-90.

5. Archer DF, Labrie F, Bouchard C, et al. Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). *Menopause.* 2015;22:950-63.

6. Bouchard C, Labrie F, Archer DF, et al. Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy. *Climacteric.* 2015;18:590-607.

7. Labrie F, Archer DF, Koltun W, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. *Menopause.* 2016;23:243-56.